Study of IBI110 and Sintilimab with Chemo for Head and Neck Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs (IBI110 and sintilimab) with chemotherapy before surgery for people with advanced head and neck cancer that can be removed surgically. The goal is to see if this approach helps shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have squamous cell carcinoma of the head and neck (oropharynx, oral cavity, larynx, or hypopharynx) that is locally advanced and can be surgically removed.
- You have at least one tumor that can be measured.
- You are in good general health (ECOG score 0 or 1) and have adequate organ function (blood counts, kidney and liver function, etc.).
- You have not had other cancers in the last 5 years (except certain skin or thyroid cancers) and are not on high-dose steroids or other immune-suppressing drugs.
- You agree to use effective birth control during and for several months after treatment, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two immunotherapy drugs (ivonescimab and pembrolizumab) given with standard chemotherapy before and possibly after surgery for advanced head and neck cancer that can be removed. The aim is to see which drug is better at shrinking the tumor and improving outcomes.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests a new immunotherapy drug (adelbelimab) combined with chemotherapy given before surgery, for people with head and neck cancer. The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests whether giving immunotherapy (sintilimab) together with chemotherapy before surgery can help treat oral cavity cancer. The goal is to shrink the tumor and possibly improve outcomes for patients with early-stage cancer that hasn't spread.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.